For decades, the architecture of medical research has been built on an incomplete blueprint — one that systematically underweights the bodies, conditions, and suffering of half the world's population. A new analytical tool developed by the World Economic Forum and its partners has now made this imbalance legible: just one-fifth of global health R&D funding addresses conditions that disproportionately affect women, and fewer than three percent of clinical trials are designed to study women specifically. What presents itself as a gap in fairness is also, by any measure, a failure of collective r
Fortune
· May 18, 2026
· health
· 4 min read
High
Sourcing: Verified
Women's health gets only 20% of R&D funding despite $1 trillion economic opportunity
Women with underfunded health conditions experience delayed diagnoses, inadequate treatments, and preventable disability due to lack of sex-specific clinical evidence and innovation.
◉
Health & Medicine
8412 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Bias & Framing
⚖
Article presents women's health funding disparity as systemic problem with significant economic upside, using WEF data to frame underinvestment as both equity and business opportunity.
Bias Direction
center-left
Confidence
MED
Problem-solution framing combined with economic opportunity angle. The article frames women's health underfunding as a 'systemic flaw' requiring innovation and investment, while emphasizing the $1 trillion economic benefit to appeal to business-minded readers. This dual framing (equity + profit) is characteristic of progressive business journalism.
systemic flaws
crowded out
untapped social and economic opportunity
strained health systems
transformative effect
equitable innovation
Reasons why women's health receives lower R&D funding (resource allocation rationale, historical precedent, market size arguments)
Counterarguments or skepticism about the $1 trillion projection methodology
Perspectives from pharmaceutical/biotech industry on investment barriers or challenges
Data on whether funding disparities exist across specific disease categories or are uniform
International variation in women's health R&D investment patterns
Geopolitical Impact
🌎
Women's health R&D underfunding ($1T opportunity) reflects systemic inequities with geopolitical implications for healthcare innovation leadership and economic competitiveness among nations.
Escalation Risk
low
Confidence
HIGH
Global
Developed economies (US, EU, UK, Canada, Australia)
Emerging markets (India, Brazil, Southeast Asia)
Low-income countries (Sub-Saharan Africa, South Asia)
Nations investing in women's health innovation will gain competitive advantage in biotech/pharma sectors and soft power through health diplomacy. Gates Foundation and WEF leadership signals Western institutional influence in setting global health priorities. Countries with robust women's health R&D ecosystems (Nordic nations, Canada) may attract talent and investment, while others risk falling behind in precision medicine and digital health innovation.
Similar to the 1970s-80s women's health movement that challenged male-centric medical research; current funding gap mirrors historical patterns of resource allocation reflecting power structures rather than epidemiological need.
Economic Lens
📈
Women's health R&D funding gap ($1T opportunity by 2040) signals underinvestment in high-growth healthcare sector with significant GDP expansion potential and market inefficiency.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical & Biotech
Medical Devices
Healthcare Services
Digital Health/Health Tech
Clinical Research
Insurance & Healthcare Finance
Women face delayed diagnoses, inadequate treatments, and higher healthcare costs due to limited research. Broader population benefits from improved preventative care and reduced disease burden. Household healthcare expenses could decrease with innovation-driven efficiency gains.
Governments likely to implement R&D tax incentives, mandate women-inclusive clinical trials, increase public health funding allocation to women's health, and establish regulatory frameworks encouraging innovation. International coordination on health equity standards probable.